Epicrispr Biotechnologies
Develops programmable epigenetic medicines to treat genetic diseases like FSHD
$90MSeries C
Role not disclosedLoading investors…
Loading investors…
Activity from announced rounds
Develops programmable epigenetic medicines to treat genetic diseases like FSHD
Fabless semiconductor company building connectivity chips for hyperscale, edge, and AI data centers
Develops lead-212 targeted alpha therapies to treat cancer
Develops allogeneic, off-the-shelf CAR-T cell therapies for hematological malignancies
Develops advanced 3D scanning probe metrology and inspection systems for semiconductor manufacturing
Develops next-generation RNAi therapeutics and engineering platform for multiple disease areas
Develops inobrodib, a first-in-class oral p300/CBP inhibitor for relapsed or refractory multiple myeloma
Builds and operates small GEO satellites for commercial and government communications
Develops advanced thermal cooling technologies for AI data centers and edge devices
Develops commercial fusion technology for neutron testing radioisotope production and fusion energy
Builds the fastest AI infrastructure in the world
Provides cloud storage for AI-first applications
Develops next-generation therapies for immune-mediated inflammatory and fibrotic diseases
Develops medicines targeting historically undruggable protein targets in cancer
Builds perception systems for Physical AI operating in complex environments